Form 4 Filing for George Golumbeski at Acumen Pharmaceuticals, Inc.

George Golumbeski, a director at Acumen Pharmaceuticals, Inc. (ABOS), acquired 35,500 shares of Common Stock and 53,250 Stock Options on June 3, 2026. The Common Stock acquisition was part of a restricted stock unit (RSU) award, which will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, contingent upon continuous service. Similarly, the stock options, with an exercise price of $2.29 and an expiration date of June 3, 2036, will vest under the same conditions. Both transactions are marked as direct ownership. The filing, designated as Form 4, was signed on June 5, 2026, by Derek Meisner as Attorney-in-Fact.